BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

10940

532488

DIVISLAB

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

DIVI S LABORATORIES LTD performance

Today’s low

Today’s high

₹ 6015.50 ₹ 6136.00
₹ 6087.00

52 week low

52 week high

₹ 3724.00 ₹ 6308.50
₹ 6087.00

Open Price

₹ 6115.50

Prev. Close

₹ 6108.00

Volume (Shares)

489551.00

Total traded value

₹ 29798.96

Upper Circuit

₹ 6718.50

Lower Circuit

₹ 5497.50

info

DIVI S LABORATORIES LTD Share Price Update

As of the latest trading session, DIVI S LABORATORIES LTD share price is currently at ₹ 6087, which is down by ₹ -21.00 from its previous closing. Today, the stock has fluctuated between ₹ 6015.50 and ₹ 6136.00. Over the past year, DIVI S LABORATORIES LTD has achieved a return of 53.11 %. In the last month alone, the return has been 10.06 %. Read More...

DIVI S LABORATORIES LTD fundamentals


  • Market cap (Cr)

    1,61,590.70

  • P/E Ratio (TTM)

    78.27

  • Beta

    0.73

  • Book Value / share

    513.62

  • Return on equity

    12.04%

  • EPS (TTM)

    78.09

  • Dividend yield

    0.49%

  • Net profit/quarter (Cr)

    594.00

info icon alternate text
  • Market cap (Cr)

    1,61,073.10

  • P/E Ratio (TTM)

    78.27

  • Beta

    0.71

  • Book Value / share

    513.62

  • Return on equity

    12.04%

  • EPS (TTM)

    78.09

  • Dividend yield

    0.49%

  • Net profit/quarter (Cr)

    594.00

info icon alternate text

DIVI S LABORATORIES LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 2297.00
Operating Expense 1649.00
Net Profit 594.00
Net Profit Margin (%) 25.85
Earnings Per Share (EPS) 22.39
EBITDA 829.00
Effective Tax Rate (%) 18.63
Particulars SEP 2024 (Values in Cr)
Revenue 2302.00
Operating Expense 1672.00
Net Profit 518.00
Net Profit Margin (%) 22.50
Earnings Per Share (EPS) 19.51
EBITDA 834.00
Effective Tax Rate (%) 29.52
Particulars JUN 2024 (Values in Cr)
Revenue 2063.00
Operating Expense 1539.00
Net Profit 430.00
Net Profit Margin (%) 20.84
Earnings Per Share (EPS) 16.18
EBITDA 700.00
Effective Tax Rate (%) 28.68
Particulars MAR 2024 (Values in Cr)
Revenue 2259.00
Operating Expense 1638.00
Net Profit 531.00
Net Profit Margin (%) 23.50
Earnings Per Share (EPS) 19.99
EBITDA 796.00
Effective Tax Rate (%) 24.14
Particulars DEC 2023 (Values in Cr)
Revenue 1808.00
Operating Expense 1412.00
Net Profit 358.00
Net Profit Margin (%) 19.80
Earnings Per Share (EPS) 13.50
EBITDA 585.00
Effective Tax Rate (%) 26.93
Particulars MAR 2024 (Values in Cr)
Revenue 7665.00
Operating Expense 5870.00
Net Profit 1576.00
Net Profit Margin (%) 20.56
Earnings Per Share (EPS) 59.37
EBITDA 2511.00
Effective Tax Rate (%) 26.07
Particulars MAR 2023 (Values in Cr)
Revenue 7625.00
Operating Expense 5620.00
Net Profit 1808.00
Net Profit Margin (%) 23.71
Earnings Per Share (EPS) 68.11
EBITDA 2697.00
Effective Tax Rate (%) 23.19
Particulars MAR 2022 (Values in Cr)
Revenue 8879.82
Operating Expense 5314.55
Net Profit 2948.54
Net Profit Margin (%) 33.20
Earnings Per Share (EPS) 111.07
EBITDA 3987.72
Effective Tax Rate (%) 19.80
Particulars MAR 2021 (Values in Cr)
Revenue 6798.61
Operating Expense 4233.26
Net Profit 1954.72
Net Profit Margin (%) 28.75
Earnings Per Share (EPS) 73.63
EBITDA 2883.21
Effective Tax Rate (%) 25.61
Particulars MAR 2020 (Values in Cr)
Revenue 5310.57
Operating Expense 3687.14
Net Profit 1372.71
Net Profit Margin (%) 25.84
Earnings Per Share (EPS) 51.71
EBITDA 2005.30
Effective Tax Rate (%) 24.29
Particulars MAR 2024 (Values in Cr)
Book Value / Share 512.11
ROE % 12.15
ROCE % 16.41
Total Debt to Total Equity 0.00
EBITDA Margin 32.44
Particulars MAR 2023 (Values in Cr)
Book Value / Share 481.77
ROE % 14.89
ROCE % 19.31
Total Debt to Total Equity 0.00
EBITDA Margin 34.94
Particulars MAR 2022 (Values in Cr)
Book Value / Share 441.82
ROE % 28.16
ROCE % 34.96
Total Debt to Total Equity 0.00
EBITDA Margin 44.61
Particulars MAR 2021 (Values in Cr)
Book Value / Share 350.15
ROE % 23.90
ROCE % 31.97
Total Debt to Total Equity 0.00
EBITDA Margin 41.95
Particulars MAR 2020 (Values in Cr)
Book Value / Share 275.38
ROE % 19.30
ROCE % 25.29
Total Debt to Total Equity 0.01
EBITDA Margin 37.31
Particulars MAR 2024 (Values in Cr)
Book Value / Share 508.83
ROE % 12.04
ROCE % 16.27
Total Debt to Total Equity 0.00
EBITDA Margin 32.77
Particulars MAR 2023 (Values in Cr)
Book Value / Share 479.43
ROE % 14.82
ROCE % 19.27
Total Debt to Total Equity 0.00
EBITDA Margin 35.38
Particulars MAR 2022 (Values in Cr)
Book Value / Share 440.44
ROE % 28.13
ROCE % 35.01
Total Debt to Total Equity 0.00
EBITDA Margin 44.92
Particulars MAR 2021 (Values in Cr)
Book Value / Share 349.28
ROE % 23.57
ROCE % 31.55
Total Debt to Total Equity 0.00
EBITDA Margin 42.43
Particulars MAR 2020 (Values in Cr)
Book Value / Share 275.63
ROE % 19.21
ROCE % 25.17
Total Debt to Total Equity 0.01
EBITDA Margin 37.78
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 3980.00
Total Assets 15470.00
Total Liabilities 15470.00
Total Equity 13571.00
Share Outstanding 265468580
Price to Book Ratio 6.75
Return on Assets (%) 10.34
Return on Capital (%) 11.79
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 4214.00
Total Assets 14439.00
Total Liabilities 14439.00
Total Equity 12767.00
Share Outstanding 265468580
Price to Book Ratio 5.89
Return on Assets (%) 12.63
Return on Capital (%) 14.29
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2818.88
Total Assets 13374.71
Total Liabilities 13374.71
Total Equity 11728.18
Share Outstanding 265468580
Price to Book Ratio 10.00
Return on Assets (%) 22.13
Return on Capital (%) 25.24
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2156.03
Total Assets 10774.07
Total Liabilities 10774.07
Total Equity 9294.61
Share Outstanding 265468580
Price to Book Ratio 10.39
Return on Assets (%) 18.41
Return on Capital (%) 21.35
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 122.63
Total Assets 8535.70
Total Liabilities 8535.70
Total Equity 7309.92
Share Outstanding 265468580
Price to Book Ratio 7.21
Return on Assets (%) 16.12
Return on Capital (%) 18.74
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 3961.00
Total Assets 15362.00
Total Liabilities 15362.00
Total Equity 13484.00
Share Outstanding 265468580
Price to Book Ratio 6.75
Return on Assets (%) 10.25
Return on Capital (%) 11.69
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 4188.00
Total Assets 14352.00
Total Liabilities 14352.00
Total Equity 12705.00
Share Outstanding 265468580
Price to Book Ratio 5.89
Return on Assets (%) 12.59
Return on Capital (%) 14.23
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2803.68
Total Assets 13307.86
Total Liabilities 13307.86
Total Equity 11691.35
Share Outstanding 265468580
Price to Book Ratio 10.00
Return on Assets (%) 22.15
Return on Capital (%) 25.22
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2142.01
Total Assets 10723.77
Total Liabilities 10723.77
Total Equity 9271.57
Share Outstanding 265468580
Price to Book Ratio 10.39
Return on Assets (%) 18.22
Return on Capital (%) 21.08
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 107.36
Total Assets 8514.11
Total Liabilities 8514.11
Total Equity 7316.69
Share Outstanding 265468580
Price to Book Ratio 7.21
Return on Assets (%) 16.12
Return on Capital (%) 18.68
Particulars MAR 2024 (Values in Cr)
Net Income 2163.00
Cash from Operations 1637.00
Cash from Investing -269.00
Cash from Financing -799.00
Net change in Cash 193.00
Free Cash Flow 2640.00
Particulars MAR 2023 (Values in Cr)
Net Income 2369.00
Cash from Operations 2932.00
Cash from Investing -2707.00
Cash from Financing -797.00
Net change in Cash -1045.00
Free Cash Flow 3405.00
Particulars MAR 2022 (Values in Cr)
Net Income 3683.50
Cash from Operations 2552.78
Cash from Investing -2194.92
Cash from Financing -532.44
Net change in Cash -815.56
Free Cash Flow 3265.98
Particulars MAR 2021 (Values in Cr)
Net Income 2666.04
Cash from Operations 2591.25
Cash from Investing 75.13
Cash from Financing -34.89
Net change in Cash 1987.17
Free Cash Flow 3501.44
Particulars MAR 2020 (Values in Cr)
Net Income 1819.46
Cash from Operations 1661.17
Cash from Investing -83.47
Cash from Financing -1091.42
Net change in Cash 41.05
Free Cash Flow 2844.38
Particulars MAR 2024 (Values in Cr)
Net Income 2132.00
Cash from Operations 1639.00
Cash from Investing -268.00
Cash from Financing -798.00
Net change in Cash 200.00
Free Cash Flow 2641.00
Particulars MAR 2023 (Values in Cr)
Net Income 2354.00
Cash from Operations 2919.00
Cash from Investing -2707.00
Cash from Financing -796.00
Net change in Cash -1056.00
Free Cash Flow 3391.00
Particulars MAR 2022 (Values in Cr)
Net Income 3676.52
Cash from Operations 2539.95
Cash from Investing -2195.40
Cash from Financing -531.50
Net change in Cash -816.74
Free Cash Flow 3253.62
Particulars MAR 2021 (Values in Cr)
Net Income 2627.87
Cash from Operations 2580.01
Cash from Investing 75.34
Cash from Financing -33.97
Net change in Cash 1988.42
Free Cash Flow 3489.99
Particulars MAR 2020 (Values in Cr)
Net Income 1813.29
Cash from Operations 1654.44
Cash from Investing -81.38
Cash from Financing -1091.25
Net change in Cash 35.84
Free Cash Flow 2837.30
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 19.95 2.02 284.31 34.11 / 77.70
BLISS GVS PHARMA LTD 122.65 16.07 1.27 1292.37 92.25 / 184.95
CIPLA LTD 1541.00 24.94 4.38 124457.39 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 272.25 22.56 2.76 801.26 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 22.35 6.30 284.31 34.11 / 77.70
AMRUTAJAN HEALTH LTD 679.10 39.81 6.59 1963.32 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8795.90 131.18 32.36 21989.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 122.65 15.93 1.26 1292.37 92.25 / 184.95

DIVI S LABORATORIES LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
6087.00 -0.34 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 6030.40
  • 26 Days 5808.20
  • 10 Days 5934.90
  • 50 Days 5780.10
  • 12 Days 5905.80
  • 100 Days 5735.60
  • 20 Days 5834.10
  • 200 Days 5474.10
6047.83 PIVOT

First Support

5970.67

First Resistance

6103.67

Second Support

5914.83

Second Resistance

6180.83

Third Support

5837.67

Third Resistance

6236.67

RSI

60.60

ADX

16.07

MACD

97.61

Williams % R

-14.81

Commodity Channel Index (CCI)

98.80

Date

2025-04-29

Week

483252.00

Same Day

377048.00

Month

345191.00

1 Year

0.73

3 Year

0.63

Over 1 Month

10.06%

down

Over 1 Year

53.11%

down

Over 3 Months

8.68%

down

Over 3 Years

10.67%

down

Over 6 Months

5.24%

down

Over 5 Years

20.84%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

DIVI S LABORATORIES LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
9.39%
Promoter Holdings
51.89%
FII
18.01%
DII
20.7%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Nilima Prasad Divi 5.4E7 (20.34%) Shareholding of Promoter and Promoter Group
Satchandra Kiran Divi 5.4E7 (20.34%) Shareholding of Promoter and Promoter Group
Life Insurance Corporation Of India 1.495271E7 (5.63%) Public Shareholding
Swarna Latha Divi 1.4E7 (5.27%) Shareholding of Promoter and Promoter Group
Sbi Mutual Fund 1.3191602E7 (4.97%) Public Shareholding
Divi's Biotech Private Limited 8000000.0 (3.01%) Shareholding of Promoter and Promoter Group
Murali Krishna Prasad Divi 7567000.0 (2.85%) Shareholding of Promoter and Promoter Group
Government Of Singapore 6011266.0 (2.26%) Public Shareholding
Axis Mutual Fund Trustee Limited 3691238.0 (1.39%) Public Shareholding
Government Pension Fund Global 3513711.0 (1.32%) Public Shareholding
Nippon Life India Trustee Ltd 3182210.0 (1.2%) Public Shareholding
Madhusudana Rao Divi 188090.0 (0.07%) Shareholding of Promoter and Promoter Group
Radhakrishna Rao Divi 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

DIVI S LABORATORIES LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
11 Aug 2023 30.0 Final 11 Aug 2023 Equity shares
11 Aug 2022 30.0 Final 12 Aug 2022 Equity shares
17 Aug 2021 20.0 Final 20 Aug 2021 Equity shares
25 Feb 2020 16.0 Interim 26 Feb 2020 Equity shares
14 Aug 2019 16.0 Final 17 Aug 2019 Equity shares
31 Aug 2018 10.0 Final 04 Sep 2018 Equity shares
15 Sep 2017 10.0 Final 19 Sep 2017 Equity shares
17 Mar 2016 10.0 Interim 18 Mar 2016 Equity shares
06 Aug 2015 20.0 Final 10 Aug 2015 Equity shares
31 Jul 2014 20.0 Final 04 Aug 2014 Equity shares
25 Jul 2013 15.0 Final 29 Jul 2013 Equity shares
26 Jul 2012 13.0 Final 30 Jul 2012 Equity shares
16 Jun 2011 10.0 Final 18 Jun 2011 Equity shares
02 Jul 2010 6.0 Final 06 Jul 2010 Equity shares
15 Jun 2009 6.0 Final 17 Jun 2009 Equity shares
26 Jun 2008 4.0 Final 28 Jun 2008 Equity shares
23 Mar 2007 2.0 Interim 26 Mar 2007 Equity shares
11 Aug 2005 0.0 Final 13 Aug 2005 Equity shares
Ex-Date Ex-Bonus Ratio
26 Sep 2015 23 Sep 2015 1:1
01 Aug 2009 30 Jul 2009 1:1
Ex-Date Old FV NEW FV Record Date
03 Aug 2007 10.0 2.0 10 Aug 2007
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
11 Aug 2023 30.0 Final 11 Aug 2023 Equity shares
11 Aug 2022 30.0 Final 12 Aug 2022 Equity shares
17 Aug 2021 20.0 Final 20 Aug 2021 Equity shares
25 Feb 2020 16.0 Interim 26 Feb 2020 Equity shares
14 Aug 2019 16.0 Final 17 Aug 2019 Equity shares
31 Aug 2018 10.0 Final 04 Sep 2018 Equity shares
15 Sep 2017 10.0 Final 19 Sep 2017 Equity shares
17 Mar 2016 10.0 Interim 18 Mar 2016 Equity shares
06 Aug 2015 20.0 Final 10 Aug 2015 Equity shares
31 Jul 2014 20.0 Final 04 Aug 2014 Equity shares
25 Jul 2013 15.0 Final 29 Jul 2013 Equity shares
26 Jul 2012 13.0 Final 30 Jul 2012 Equity shares
16 Jun 2011 10.0 Final 18 Jun 2011 Equity shares
02 Jul 2010 6.0 Final 06 Jul 2010 Equity shares
15 Jun 2009 6.0 Final 17 Jun 2009 Equity shares
26 Jun 2008 4.0 Final 28 Jun 2008 Equity shares
23 Mar 2007 2.0 Interim 26 Mar 2007 Equity shares
11 Aug 2005 0.0 Final 13 Aug 2005 Equity shares
Ex-Date Ex-Bonus Ratio
26 Sep 2015 23 Sep 2015 1:1
01 Aug 2009 30 Jul 2009 1:1
Ex-Date Old FV NEW FV Record Date
03 Aug 2007 10.0 2.0 10 Aug 2007

Divi’s Lab share result highlights

Divi’s Lab’s recent financial results highlight the company’s steady performance in the pharmaceutical sector. The Divi’s Lab share price reacted moderately to the quarterly earnings, which showed a slight increase in revenue. Despite a challenging market environment, the company managed to improve its profit margins through effective cost control measures. EBITDA remained stable, and net profit also saw modest growth, aligning with market expectations. Investors are particularly interested in how Divi’s Lab’s strategic investments and expansion plans will influence future results and the Divi’s Lab share price. Overall, the company’s financial health remains solid, with promising long-term prospects.

Divi’s Lab share annual reports

Divi’s Lab’s annual reports provide a comprehensive overview of the company’s financial stability and strategic goals. Over the past year, the company has shown consistent revenue growth, reflecting its strong position in the industry. The Divi’s Lab share price has mirrored this performance, showing resilience despite broader market volatility. The balance sheet indicates a healthy financial position, supported by strong cash flows and controlled operational costs. The report also outlines the company’s future expansion plans, which are expected to positively impact the Divi’s Lab share price in the coming years.

Divi’s Lab share dividend

Divi’s Lab has maintained a consistent dividend policy, providing shareholders with regular returns. The Divi’s Lab share price often reflects positive sentiment following dividend announcements, as the company is known for its stable financial health. The most recent dividend was modest, in line with its previous years, allowing the company to retain capital for further growth initiatives. Divi’s Lab’s approach to dividend distribution balances rewarding shareholders while ensuring the company’s long-term growth remains on track. Investors continue to monitor future dividends as a key aspect of the company’s financial strategy and its impact on the Divi’s Lab share price.

Divi's Laboratories Limited Overview

Since its inception in 1990, Divis Laboratories Ltd has carved a niche in manufacturing and exporting APIs, intermediates, and Nutraceutical ingredients, catering to the global pharmaceutical and nutraceutical industries. With a portfolio that includes 30 high-volume generic APIs, custom synthesis services for top pharma companies, and a specialised unit for carotenoids in Visakhapatnam, Divis stands out for its extensive range and global reach. The company boasts six multi-purpose manufacturing facilities in Telangana and Visakhapatnam, recognized among the largest API production sites worldwide, with a significant reactor capacity and multiple cGMP and customer quality audits. Offering a diverse product list across various therapeutic categories, Divis Laboratories is a global leader in Naproxen and has a strong international presence with marketing subsidiaries in the USA and Switzerland. The majority of its revenue comes from product sales, heavily weighted towards exports, especially to Europe and North America. Moving forward, Divis is expanding with a new manufacturing site in Kakinada and investing in cutting-edge technologies, underscoring its commitment to innovation and growth in the pharmaceutical sector.
 

DIVI S LABORATORIES LTD Share Price

Divi's Laboratories Limited is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals. The Company is one of the world's largest API companies, with two manufacturing units and a market presence across 100 countries. It is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management. It is among the largest pharmaceutical companies in India with a portfolio of approx. 160 products across diverse therapeutic areas. Presently, it has 6 manufacturing facilities and market presence across several countries.

The company has two subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products and to provide a greater reach to customers within these regions. The company has Research Centers at Sanathnagar, Hyderabad and at the manufacturing sites. Research Centre at Sanathnagar primarily focuses on custom synthesis, contract research for MNC companies as also future generics involving processes like route design, route selection, establishing gram scale process and structural confirmation.

Divi's Laboratories Limited was established in year 1990 as Divis Research Center Limited (DRC) with Research & Development as their prime fundamental. In 1994, they changed their name to Divis Laboratories Limited to reflect their growing area of operations.

During the year 1991-93, the company developed several commercial processes for intermediates and bulk actives and supplies to manufacturing majors.

In the year 1995, the company started operations in their manufacturing facility (Unit I) at Choutuppal near Hyderabad. In the year 1997, the company was certified as ISO-9002 compliant by SGS-Yarsley of U.K. In the year 1999, European Directorate gave a 'Certificate of Suitability' (CoS) for Naproxen produced by the company. In the year 2001, the company received OHSAS-18001 Certification from BVQI of London for their Occupational Health and Safety Management Systems.

In the year 2002, the company commenced setting up of their second manufacturing facility (Unit II) at Chippada near Visakhapatnam. In the year 2003, they opened a new research center christened 'DRC-Vizag' for fundamental research in selected niche business core segments. The company went for initial public offering (IPO) and their shares were listed on Bombay Stock Exchange and National Stock Exchange.

In the year 2004, the company invested an amount of Rs 3035.21 lakh towards capital expenditure at their manufacturing facilities at Choutuppal (Unit-I) and Chippada (Unit-II) for additional machinery installed at both Unit-I and Unit-II.

In the year 2006, the company received letter of approval from Ministry of Commerce, Government of India, for setting up a sector-specific special economic zone (SEZ) for pharmaceutical ingredients at Chippada, Bheemunipatnam in Visakhapatnam with investment of Rs 200 crore. The company's second manufacturing site at Chippada, was converted into Export Oriented Unit (EOU) and started operations as EOU from June 1, 2006.

During the year 2006-07, the company developed an SEZ titled 'Divi's Pharma SEZ' on a 250-acre site at Chippada, Visakhapatnam. During the year 2007-08, the company set up new production as well as utility facilities in SEZ and EOU Units, and enhanced existing capacities at Unit-1. They commissioned Nutraceuticals Manufacturing facility at Divi's Pharma SEZ and commenced commercial operations effective June 1, 2008.

During the year 2008-09, the company added 9 products to their product portfolio of which 4 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates. During the year 2009-10, they added 7 products to their product portfolio of which 2 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates.

During the year 2010-11, the company added 21 products to their product portfolio of which 8 are generic APIs and intermediates and 13 are custom synthesis APIs and intermediates. The company set up a new facility called 'DSN SEZ Unit' at Chippada in Visakhapatnam at an estimated cost of Rs 200 crore for creating additional capacities for the new opportunities in generic as well as custom synthesis segment. The DSN SEZ Unit commenced commercial operations from June 1, 2011.

During the year 2012-13, the company added 9 products to its product portfolio of which 3 are generic APIs and intermediates and 6 are custom synthesis APIs and intermediates.

In 2014, the Korean Food and Drug Administration (KFDA) carried out inspection of the company's Visakhapatnam Unit-2 for the third time. During the year, fourth US FDA inspection was carried out at the company's Visakhapatnam Unit-2. Also during the year, fifth US FDA inspection was carried out for Unit-1. During the year, COFEPRIS (Mexico) inspected the company's Visakhapatnam Unit-2 for the first time. COFEPRIS (Mexico) also inspected the company's Choutuppal Unit-1 in Telangana for the first time in the year 2014.

On 19 February 2016, Divi's Laboratories announced that it has had a successful inspection by the US-FDA for its Unit-2 at Chippada, Bheemunipatnam near Visakhapatnam during February 2016 with no observations.

The Board of Directors of Divi's Laboratories at its meeting held on 12 August 2016 approved and ratified one-time ex-gratia of an aggregate amount of Rs 79 crore to the employees and whole-time directors of the company on the occasion of completion of 25 years of formation of the company.

On 8 April 2017, Divi's Laboratories announced that the US-FDA has exempted some more products manufactured at the company's Unit-II at Visakhapatnam from import alert issued under clauses 66-40 and 99-32 of the FDA regulations.

On 22 April 2017, Divi's Laboratories announced that the US-FDA has issued a warning letter for the company's Unit-II at Visakhapatnam. On 4 August 2017, Divi's Laboratories announced that the inspection of the Unit-2 Visakhapatnam was completed successfully by HPRA (Ireland) and JAZMP (Slovenia). The inspection was focused on follow up on the effectiveness of the CAPA implemented from the last JAZMP inspection and general GMP inspection of the site.

On 15 November 2017, Divi's Laboratories announced that the US-FDA has lifted/removed import alert 66-40 imposed on the company's Unit-II at Visakhapatnam.

On 18 November 2017, Divi's Laboratories announced that the company has received an Establishment Inspection Report (EIR) from US-FDA for Unit-II at Visakhapatnam, as closure of audit by FDA.

On 16 May 2018, Divi's Laboratories announced that its Unit-I at Choutuppal, Telangana has had an inspection by the US-FDA from 14th May 2018 to 16th May, 2018. This was a general cGMP inspection by the FDA. The inspection has been concluded with no 483 observations.

As on 31 March 2018, the company has two overseas subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products.

During the year 2017-18, the company is making capacity additions at the existing manufacturing facilities and in this process we are building 2 additional production blocks at Unit-1 at Choutuppal. Capital WIP as at the year-end amounted to Rs 11976 lakhs. Capital expenditure incurred at the existing Units is to enhance capacities as well as upgrading utilities and infrastructure for compliances. As the company has significant accumulation of cash reserves, all capex has been funded with internal accruals.

In order to cater to the increasing opportunities in generic and big pharma business, the Company during the FY2019, is taking up following two brownfield projects with an aggregate investment of Rs 1200 crore.a. An SEZ Unit at our Unit-II at Visakhapatnam, named as DCV SEZ Unit, with an investment of Rs 600 crore. (revised from the estimate of Rs 400 crore announced at the last General Meeting),b. Another SEZ Project with an investment of Rs 600 crore in the available land at our Unit-I in Bhuvangiri-Yadadri (erstwhile Nalgonda) District, Telangana State.

The Company has commenced commercial operations from a part of the DC-SEZ Unit in February, 2020, and from a part of the DCV-SEZ Unit in March 2020. The Company has also taken up debottlenecking programs at Unit-I as well as Unit-II by investing an aggregate amount of Rs 300 crore -which would also create additional capacities for existing products. In addition, the company also taken up augmentation of waste treatment infrastructure at Unit-II at an estimated cost of Rs 150 crore. A part of the backward integration, debottlenecking and utility expansion projects have come into utilization this year. The rest of these projects will be completed and come into utilization by end of second half of financial year 2020-21. The balance works of the brownfield projects of DC-SEZ and DCVSEZ are also expected to be completed by second half of financial year 2020-21.

As on 31 March 2020, the company has two overseas subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products.

Eventhough there was a nationwide lockdown restrictions due to COVID-19 pandemic since March 24, 2020, the Government has exempted manufacturing units of essential goods including drugs and pharmaceuticals, medical devices, their raw materials and intermediates from the lockdown restrictions, amongst others. The Company has been operating in compliance with the various advisories/ guidelines passed by the Government of India, State Governments and statutory institutions.

The new brownfield DC and DCV SEZ Units and the debottlenecking / backward integration programs taken up by the company during the last year, have become fully operational during the FY2021. Also Modernization and upgradation of waste water treatment plants at the manufacturing sites has been implemented. During the year 2020-21, the company also taken up another capex program with an estimated investment of Rs 400 crore for fast-tracking a customs synthesis project.

During the year 2023, the Company implemented its project of setting up a manufacturing plant (Unit-III) at Kakinada District of Andhra Pradesh.

Parent organization Indian Private
NSE symbol DIVISLAB
Founded 1990
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Divis Laboratories Ltd?

Answer Field

The share price of Divis Laboratories Ltd for NSE is ₹ 6087 and for BSE is ₹ 6067.5.

What is the Market Cap of Divis Laboratories Ltd?

Answer Field

The market cap of Divis Laboratories Ltd for NSE is ₹ 16,15,90.70 Cr. and for BSE is ₹ 16,10,73.10 Cr. as of now.

What is the 52 Week High and Low of Divis Laboratories Ltd?

Answer Field

The 52 Week High and Low of Divis Laboratories Ltd for NSE is ₹ 6308.50 and ₹ 3724.00 and for BSE is ₹ 6448.75 and ₹ 3725.55.

How to Buy Divis Laboratories Ltd share?

Answer Field

You can trade in Divis Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Divis Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been 53.11%.

What is the Current Share Price of Divis Laboratories Ltd?

Answer Field

Divis Laboratories Ltd share price is for NSE ₹ 6087 & for BSE ₹ 6067.5 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Divis Laboratories Ltd Share?

Answer Field

The market cap of Divis Laboratories Ltd for NSE ₹ 16,15,90.70 & for BSE ₹ 16,10,73.10 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Divis Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Divis Laboratories Ltd share is 78.27.

What is the PB ratio of Divis Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Divis Laboratories Ltd share is 513.62.

How to Buy Divis Laboratories Ltd Share?

Answer Field

You can trade in Divis Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Divis Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Divis Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Divis Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

Who is the CEO of Divi’s Lab?

Answer Field

The CEO of Divi’s Lab oversees the company’s strategic operations and long-term vision. Under their leadership, Divi’s Lab has maintained its strong market position, and their decisions play a crucial role in shaping the company’s performance. The CEO’s leadership directly influences the Divi’s Lab share price as they focus on sustaining growth and expanding the company’s global footprint. Investors closely watch the CEO’s direction as it impacts both the company’s performance and its market valuation.

When was Divi’s Lab established?

Answer Field

Divi’s Lab was established several decades ago, marking its entry into the pharmaceutical sector with a focus on innovation and research. Since its inception, the company has seen steady growth in both its operations and market value. The establishment of Divi’s Lab set the foundation for its current market success, with the Divi’s Lab share price reflecting its long-standing reputation in the industry. Over the years, the company has consistently expanded, becoming a key player in the pharmaceutical market.

What factors influence the Divi’s Lab share price?

Answer Field

Several factors influence the Divi’s Lab share price, including the company’s financial performance, product pipeline, and broader industry trends. Key internal factors such as revenue growth, profitability, and operational efficiency are critical in shaping investor sentiment. External influences like regulatory changes, market conditions, and competitive pressures also play a role. Investors and stakeholders closely monitor these variables to gauge the potential movement of the Divi’s Lab share price, especially in light of evolving market dynamics.

Is Divi’s Lab debt free?

Answer Field

Divi’s Lab maintains a relatively low debt level, positioning itself as a financially stable company. While it may have some debt, it is well-managed and does not pose significant risks to the company’s overall performance. This debt strategy helps maintain investor confidence in the company’s future, positively influencing the Divi’s Lab share price. The company’s balance sheet reflects its prudent financial management, allowing it to focus on growth while maintaining a healthy capital structure.

How has the Divi’s Lab share price performed over the past year?

Answer Field

The Divi’s Lab share price has experienced moderate fluctuations over the past year, largely influenced by the company’s quarterly results and external market conditions. While the price has seen some downturns, it has also shown resilience, particularly during periods of positive financial performance. Overall, the Divi’s Lab share price has remained stable, reflecting the company’s solid position in the pharmaceutical sector. Investors continue to monitor future performance closely to anticipate potential shifts in the share price.

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|